AIMS/HYPOTHESIS: Renal accumulation of AGEs may contribute to the progression of diabetic nephropathy. We evaluated the effect of ramipril (a pure ACE inhibitor) and AVE7688 (a dual inhibitor of ACE and neutral endopeptidase) on renal accumulation of the advanced glycation end-product (AGE) 3-deoxyglucosone-imidazolone, carboxymethyllysine (CML) and pentosidine, and on clearance of CML in type 2 diabetes. METHODS: Male Zucker diabetic fatty rats (ZDF, Gmi-fa/fa) rats were treated from age 10 to 37 weeks with ramipril (1 mg.kg(-1).day(-1)), AVE7688 (45 mg.kg(-1).day(-1)) or without drug. Ramipril and AVE7688 reduced albuminuria by 30 and 90%, respectively. RESULTS: ZDF rats showed increased renal accumulation of the AGE subtypes 3-deoxyglucosone-imidazolone, pentosidine and CML by about 40, 55 and 55%, respectively compared with heterozygous, non-diabetic control animals at the age of 37 weeks. AVE7688 but not ramipril attenuated the renal accumulation of 3-deoxyglucosone-imidazolone, pentosidine and CML and improved CML clearance in ZDF rats. During glycation reactions in vitro, AVE7688 also demonstrated potent chelating activity and inhibited metal-catalysed formation of pentosidine and CML. CONCLUSIONS/ INTERPRETATION: Improved AGE clearance and direct inhibition of AGE formation by chelation may contribute to reduced accumulation of renal AGEs and to the nephroprotective effects of vasopeptidase inhibition in type 2 diabetes.
AIMS/HYPOTHESIS: Renal accumulation of AGEs may contribute to the progression of diabetic nephropathy. We evaluated the effect of ramipril (a pure ACE inhibitor) and AVE7688 (a dual inhibitor of ACE and neutral endopeptidase) on renal accumulation of the advanced glycation end-product (AGE) 3-deoxyglucosone-imidazolone, carboxymethyllysine (CML) and pentosidine, and on clearance of CML in type 2 diabetes. METHODS: Male Zucker diabetic fattyrats (ZDF, Gmi-fa/fa) rats were treated from age 10 to 37 weeks with ramipril (1 mg.kg(-1).day(-1)), AVE7688 (45 mg.kg(-1).day(-1)) or without drug. Ramipril and AVE7688 reduced albuminuria by 30 and 90%, respectively. RESULTS:ZDFrats showed increased renal accumulation of the AGE subtypes 3-deoxyglucosone-imidazolone, pentosidine and CML by about 40, 55 and 55%, respectively compared with heterozygous, non-diabetic control animals at the age of 37 weeks. AVE7688 but not ramipril attenuated the renal accumulation of 3-deoxyglucosone-imidazolone, pentosidine and CML and improved CML clearance in ZDFrats. During glycation reactions in vitro, AVE7688 also demonstrated potent chelating activity and inhibited metal-catalysed formation of pentosidine and CML. CONCLUSIONS/ INTERPRETATION: Improved AGE clearance and direct inhibition of AGE formation by chelation may contribute to reduced accumulation of renal AGEs and to the nephroprotective effects of vasopeptidase inhibition in type 2 diabetes.
Authors: J M Forbes; T Soulis; V Thallas; S Panagiotopoulos; D M Long; S Vasan; D Wagle; G Jerums; M E Cooper Journal: Diabetologia Date: 2001-01 Impact factor: 10.122
Authors: A Bierhaus; S Schiekofer; M Schwaninger; M Andrassy; P M Humpert; J Chen; M Hong; T Luther; T Henle; I Klöting; M Morcos; M Hofmann; H Tritschler; B Weigle; M Kasper; M Smith; G Perry; A M Schmidt; D M Stern; H U Häring; E Schleicher; P P Nawroth Journal: Diabetes Date: 2001-12 Impact factor: 9.461
Authors: Vicki Thallas-Bonke; Carsten Lindschau; Bishoy Rizkalla; Leon A Bach; Geoffrey Boner; Matthias Meier; Hermann Haller; Mark E Cooper; Josephine M Forbes Journal: Diabetes Date: 2004-11 Impact factor: 9.461
Authors: Nozomu Tanji; Glen S Markowitz; Caifeng Fu; Thomas Kislinger; Akihiko Taguchi; Monika Pischetsrieder; David Stern; Ann Marie Schmidt; Vivette D D'Agati Journal: J Am Soc Nephrol Date: 2000-09 Impact factor: 10.121
Authors: T Niwa; T Katsuzaki; S Miyazaki; T Miyazaki; Y Ishizaki; F Hayase; N Tatemichi; Y Takei Journal: J Clin Invest Date: 1997-03-15 Impact factor: 14.808
Authors: Christine L Oltman; Eric P Davidson; Lawrence J Coppey; Travis L Kleinschmidt; Brian Dake; Mark A Yorek Journal: Eur J Pharmacol Date: 2010-10-30 Impact factor: 4.432
Authors: Rossana Calderon Moreno; Ana Navas-Acien; Esteban Escolar; David M Nathan; Jonathan Newman; John F Schmedtje; Denisse Diaz; Gervasio A Lamas; Vivian Fonseca Journal: J Clin Endocrinol Metab Date: 2019-07-01 Impact factor: 6.134
Authors: Simone K Frey; Britta Nagl; Andrea Henze; Jens Raila; Beate Schlosser; Thomas Berg; Martin Tepel; Walter Zidek; Martin O Weickert; Andreas F H Pfeiffer; Florian J Schweigert Journal: Lipids Health Dis Date: 2008-08-27 Impact factor: 3.876